Country: Israel
Language: English
Source: Ministry of Health
VIGABATRIN
PADAGIS ISRAEL PHARMACEUTICALS LTD, ISRAEL
N03AG04
FILM COATED TABLETS
VIGABATRIN 500 MG
PER OS
Required
PADAGIS ISRAEL PHARMACEUTICALS LTD, ISRAEL
VIGABATRIN
VIGABATRIN
Treatment in combination with other anti epileptic drugs for patients with resistant partial epilepsy with or without secondary generalisation, that is where all other appropriate drug combinations have proven inadeqate or have not been tolerated.
2022-10-31
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF MEDICINAL PRODUCT Sabrilan 500 mg, film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 500mg vigabatrin For a full list of excipients, see Section 6.1 3. PHARMACEUTICAL FORM Film-coated tablets. White to off-white, oval, biconvex tablets with a score line on one side and “SABRIL” engraved on the other side. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. Visual field defects (VFD) have been reported in patients receiving vigabatrin with a high prevalence (about 1/3 of patients). Frequencies found in an open- clinical study are presented in section 5.1. The onset is usually after months to years of vigabatrin therapy. The degree of visual field restriction may be severe. Most of the patients with perimetry-confirmed defects have been asymptomatic. Hence, this undesirable effect can only be reliably detected by systematic perimetry which is usually possible only in patients with a developmental age of more than 9 years. A specifically developed method based on field specific Visual Evoked Potentials (VEP) is available from the company on request to test the presence of peripheral vision in children aged 3 years and above. At present this method has not been validated in the detection of vigabatrin-attributed visual field defects. Electroretinography may be useful but should be used only in adults who are unable to cooperate with perimetry or in the very young (see Visual Field Defects). Available data suggests that visual field defects are irreversible even after discontinuation of vigabatrin. A deterioration of VFD after the treatment is discontinued cannot be excluded. Therefore, vigabatrin should only be used after a careful assessment of the balance of benefits and risk compared with alternatives. Vigabatrin is not recommended for use in patients with any pre-existing clinically significant visual field defect. Patients should undergo systematic screening examination when s Read the complete document